Navigation Links
BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
Date:11/7/2007

BURLINGAME, Calif., Nov. 7 /PRNewswire/ -- BioSeek, Inc., a leader in applying integrated human biology systems for developing new therapeutics, announced today that Michael C. Venuti, Ph.D., has joined the Company as its Chief Executive Officer and member of the Board of Directors. Dr. Venuti succeeds Peter D. Staple, who will continue his involvement with the Company as an investor and Board member. Dr. Venuti previously served as Chief Executive Officer of Discovery Partners International, a small molecule-based drug discovery services company.

Fred Craves, Managing Director and Founder of Bay City Capital, which is a major investor in BioSeek, commented, "We welcome Michael to BioSeek, as we believe his leadership and specific experience in drug discovery will be important as BioSeek strives to expand its proprietary drug discovery activities. This new direction was highlighted by our recent research collaboration with Amylin Pharmaceuticals to discover novel peptide therapeutics. We thank Peter Staple for his important contributions to BioSeek, including taking the Company to a new level through validating corporate partnerships, including our relationship with Amylin."

"It's gratifying to have an individual with Michael's background and talent join us as the Company advances into an exciting new phase of development," added Peter Staple.

"I look forward to leading BioSeek in its new drug discovery-focused direction and anticipate these new initiatives will lead us to both additional partnerships and revenue-generating contracts in the future," commented Dr. Venuti. "The launching of our proprietary development programs utilizing our BioMAP(R) human biology screening systems will also provide us with additional internal value drivers."

Since the Discovery Partners merger with Infinity Pharmaceuticals in September 2006, Dr. Venuti has served as a consultant to TPG Growth Biotech Ventures, as well as to a number of biotech companies. Before becoming CEO of Discovery Partners, Dr. Venuti served as Chief Scientific Officer, and had been a member of its board of directors before becoming CSO. Prior to joining Discovery Partners, he served as General Manager of Celera Genomics Group's South San Francisco site after its acquisition of Axys Pharmaceuticals, Inc. He served as Senior Vice President, Research and Preclinical Development, of Axys Pharmaceuticals prior to its acquisition by Celera. In this capacity, he was responsible for all small molecule target identification, medicinal chemistry, drug discovery and preclinical development activities. Prior to joining Axys, Dr.Venuti was Director of Bioorganic Chemistry at Genentech, Inc., and had begun his research career in medicinal chemistry at Syntex.

Dr. Venuti holds an A.B. from Dartmouth College, a Ph.D. in organic chemistry from the Massachusetts Institute of Technology, and completed postdoctoral training in the Institute of Organic Chemistry at Syntex Research. He is on the board of directors of Infinity Pharmaceuticals and serves as Executive Scientific Advisor to BIO Ventures for Global Health, a non-profit advocacy group focused on drug discovery and development for neglected diseases. Dr. Venuti holds an appointment as Adjunct Professor of Chemistry in the Department of Pharmaceutical Chemistry at the University of California, San Francisco.

About BioSeek

BioSeek is improving the success rate of pharmaceutical research and development by integrating human biology from the early stages of drug discovery onward. The Company's BioMAP(R) Systems incorporate predictive human cell-based disease models that generate uniquely informative activity signatures for each potential drug, driving the selection and development of new drug candidates. BioSeek is leveraging BioMAP(R) Systems technology in collaborations to enhance the productivity of its pharmaceutical partners' pipelines, and in the Company's internal programs to identify promising compounds for proprietary development in the fields of inflammation, cardiovascular diseases, autoimmune diseases, and related indications.

For more information, go to http://www.bioseekinc.com

BioSeek Contacts:

BioSeek, Inc.

Michael C. Venuti, Ph.D.

Chief Executive Officer

Tel: 650-552-0754

E-mail: mvenuti@bioseekinc.com

MacDougall Biomedical Communications

Jennifer Greenleaf

Tel: 508.647.0209

E-mail: jgreenleaf@macbiocom.com


'/>"/>
SOURCE BioSeek, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Novo Nordisk Appoints New Leader of North American Business
3. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
4. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
5. Resonant Medical Appoints New Vice President of Global Sales
6. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
7. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
8. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
9. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
10. Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA
11. Adlyfe Appoints Roxanne Duan as Vice President of Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... years, Doctors on Liens has published a directory of the top doctors working ... When the company started in 1997, the directory was a single page focusing on chiropractors ... directory features a vast array of medical specialists stretching from Sacramento to San ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and ... of those affected by autism spectrum disorder (ASD) and other developmental disabilities. The group, ... will give parents and other caregivers the opportunity to share stories and advice, seek ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest campaign, ... standing as living proof that attitude and determination can combine into the most ... spike around the holidays. This campaign will offer patients a new-found hope, by ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research ... labeling, storing, shipping and disposal. The new version is a faster and a ...
(Date:12/2/2016)... Wexford, PA (PRWEB) , ... December 02, 2016 , ... ... manages stress and overall health, day and night. No other wearable health technology on ... management. We wanted to give poeple more meaningful insights about their health than ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016  LifeVac, the revolutionary ... included in the Emergency Response Training and Support Services ... excited to have LifeVac become part of the ERTSS ... Founder and CEO of LifeVac. "Having an established network ... and effectively will help leverage our efforts to spread ...
(Date:12/2/2016)... -- PipelineRx, a leading medication management technology company focused ... its SaaS-based telepharmacy platform, PowerGridRx™ , at ... Clinical Meeting and Exhibition, December 5-7 in ... hospital clients nationally, the Company is a leader ... improve pharmacy operations, enhance patient safety, and reduce ...
(Date:12/2/2016)... 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today ... Inc. ("PSI").  The combination of Texas -based ... -based PSI bring together both company,s clinical expertise and high-touch ... an industry-leading specialty pharmacy. About Maxor ... , , ...
Breaking Medicine Technology: